Semaglutide effectively treats liver disease in two thirds of patients, new research has found. Results from the ESSENCE phase 3 clinical trial published today in the New England Journal of ...

A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a serious form of fatty liver disease, a new study has found.

What's more, liver fibrosis (scarring) – which happens as the liver tries to repair damage – was reduced in 36.8 percent of patients given the semaglutide treatment, compared to 22.4 percent ...

MASH, a progressive form of fatty liver disease, is marked by liver inflammation, hepatocyte injury, and fibrotic changes. Left untreated, it can lead to cirrhosis, liver failure, and ...

Secondary outcomes included combined resolution of steatohepatitis and reduction in liver fibrosis, which was reported in 32.7 and 16.1 percent of those in the semaglutide and placebo groups ...

VCU-led research highlights semaglutide’s potential for treating fatty liver disease Provided by GlobeNewswire Apr 30, 2025, 10:09:48 PM ...

Share on Pinterest Ozempic, the active ingredient of which is semaglutide, can also reduce the risk of heart disease, according to research. Steve Christo – Corbis/Corbis via Getty Images ...

Compared with other medications, semaglutide was associated with a 24% lower risk for peripheral percutaneous transluminal angioplasty (HR, 0.76; P = .045) and a 50% lower risk for lower extremity ...

Separately, in the SOUL trial of people with T2D who also had atherosclerotic cardiovascular disease and/or chronic kidney disease (CKD), several years of oral semaglutide (Rybelsus) reduced one's ...

Semaglutide is not approved to treat MASH in the U.S. Pharmaceutical maker Novo Nordisk has said it plans to seek regulatory approval for its use in treating liver disease sometime this year.